Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug

SAN DIEGO, CA, USA I May 27, 2020 I Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to announce that the Company will soon  begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.

The study will employ Nascent’s monoclonal, antibody, Pritumumab (“PTB”) and will be conducted in collaboration with a Southern CA Cancer Center as noted in their release which can be viewed at

Nascent’s lead therapeutic asset, PTB, is a natural human antibody that works by binding to ectodomain vimentin (EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.

Because EDV is found in a variety of cancers, these important clinical trials of PTB could have implications for a broad range of more common cancers, such as breast, colon and lung. The current Phase 1 trials have been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors.

Sean Carrick, CEO of Nascent Biotech, states, "Nascent is committed to opening this trial and delivering this promising treatment to patients afflicted with this devastating disease.“

For more information on the research studies and clinical trials, visit

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide.  Its products are not commercially available. For further information please visit our website Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer.  Development for PTB as a treatment for COVID-19 has been initiated. 

SOURCE: Nascent Biotech

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up